Evaluation Of Glycemic Control and Insulin Resistance in Patients with Type 2 Diabetes Mellitus Treated By Sitagliptin in A Triple Therapy with Other Antidiabetic Drugs

• Published in: Pharmacie Globale : International Journal of Comprehensive Pharmacy Vol. 8; no. 3; pp. 62 - 70
• Main Authors: Taha Al-Kattan, Zainab Mazin, Al-Youzbaki, Wahda Basheer, Ahmed, Yousif Bahaaddin
• Format: Journal Article
• Language: English
• Published: Roorkee Pharmacie Globale 01.07.2017
• Subjects: Analyzers; Antidiabetics; Diabetes; Diabetes mellitus; Drug development; Drug dosages; Drugs; Fasting; Glibenclamide; Glucose; Hemoglobin; Homeostasis; Hormones; Immunoassay; Insulin; Insulin resistance; Metabolism; Metformin; Parameter estimation; Patients; Reduction; Therapy; Iraq
• ISSN: 0976-8157; 0976-8157

To evaluate the effect of sitagliptin in combination with metformin and glibenclamide (triple therapy group) on glycemic control (fasting serum glucose (FSG) and glycated hemoglobin (HbA1c)) and homeostatic model assessment: insulin resistance (HOMA-IR)), in patients with type 2 diabetes mellitus (T2DM). This is a case control study conducted in Layla-Qassim Center for Diabetic Treatment in Erbil City, Iraq, from the 31th October 2015 to the 20th April 2016. One hundred sixty-five subjects were enrolled in this study. These participants were divided into four groups: apparently healthy group set as control (n=40), Dual therapy group T2DM (on metformin and glibenclamide treatment) (n=45), Triple therapy group T2DM (on sitagliptin, metformin and glibenclamide treatment) (n=42) and T2DM on diet group (n=38). From each subject the taken fasting blood sample was used for estimating the studied parameters using commercially available kits and by fully automated immunoassay and chemistry analyzers. This study showed a highly significant reduction in FSG (p= 0.0001) and HbA1c (p = 0.0001) in diabetic on triple therapy group when compared with diabetic on dual therapy group and on diet group. While a significant reduction in FSG (p= 0.03) but a non significant differences in HbA1c in T2DM patients on dual therapy group when compared with T2DM patients on diet group. This study found a significant reduction in HOMA-IR (p= 0.001), (p = 0.03) in diabetic on triple therapy group as compared with diabetic on diet and on dual therapy group respectively. Combination of sitagliptin with metformin and glibenclamide (triple therapy) for more than three months in patients with T2DM, is associated with improvement in glycemic control and reduction in insulin resistance.